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Background: Nasopharyngeal carcinoma (NPC) is an Epstein-Barr virus–associated malignancy that is most
common in East Asia, Africa, and Alaska. Radiotherapy is the main treatment option; unfortunately, disease response
to concurrent radiotherapy and chemotherapy varies among patients with NPC, and in many cases, NPC becomes
resistant to radiotherapy. Our previous studies indicated that Jab1/CSN5 was overexpressed and plays a role in the
pathogenesis and radiotherapy resistance in NPC. Therefore, it is important to seek for innovative therapeutics
targeting Jab1/CSN5 for NPC. In this study, we explored the antitumor effect of a curcumin analogue T83 in NPC,
and found T83 exhibits antitumor activity and induces radiosensitivity through inactivation of Jab1 in NPC.
Methods: NPC cell viability and proliferation were detected by the 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) and colony formation assays. Cell cycle distribution was detected with use of
flow cytometry. Apoptosis was examined by using the Annexin V/propidium iodide staining assay and cleavage
poly(ADP-ribose polymerase (PARP) and cleavage caspase-3 expression. Jab1 expression was examined by Western
blotting.
Results: A growth inhibitory effect was observed with T83 treatment in a dose- and time-dependent manner. T83
significantly induced G2/M arrest and apoptosis in NPC. In addition, T83 inhibited Jab1 expression and sensitized
NPC cells to radiotherapy.
Conclusion: Our data indicate that T83 exhibits potent inhibitory activity in NPC cells and induces radiotherapy
sensitivity. Thus, T83 has translational potential as a chemopreventive or therapeutic agent for NPC.
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CurcuminBackground
Human nasopharyngeal carcinoma (NPC) is one of the
most common cancers in Southern China [1], and the
highest incidence of this disease (peaking at 50 per
100,000 persons per year) is found in this area, espe-
cially among those of Cantonese origin [2]. Epstein-Barr* Correspondence: fxclaret@mdanderson.org; hlyangsums@hotmail.com
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reproduction in any medium, provided the orvirus infection, environmental factors, and genetic sus-
ceptibility are all associated with NPC [3,4]. Although
NPC is a relatively radiosensitive disease, the thera-
peutic effect of radiotherapy is not satisfactory because
of radioresistance [5]. To determine the mechanism of
radioresistance in this disease, our research group
established the radioresistant NPC cell line (CNE2R)
based on CNE2 [6]. Genetic alterations have been
reported in NPC, and our recent findings showed that one
such alteration, c-Jun activation domain-binding protein-
1/constitutive photomorphogenic-9 signalosome (Jab1/
CSN5), which negatively regulates p27, is overexpressed in
this disease [7] and thus contributes to NPC resistance to. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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inhibitors targeting Jab1 are largely undetermined.
Curcumin is a well-known chemopreventive agent
that has potent anticancer activity in a wide variety of
tumor cells [10,11]. Unfortunately, many preclinical and
clinical studies have indicated poor bioavailability and
rapid metabolism of curcumin, due to its instability
under certain physiologic conditions, which have lim-
ited its application in anticancer therapy [12]. Conse-
quently, analogues of curcumin with similar safety
profiles but with increased anticancer activity have been
developed in recent years [11,13-15]. Interestingly, Jun
Li et al. reported that PEGylated curcumin inhibits pan-
creatic cancer cell proliferation through suppression of
Jab1/CSN activity [16]. Recently, our group synthesized
a series of new 4-arylidene curcumin analogues that can
effectively inhibit proliferation of cells in a panel of
human cancer cell lines such as CNE2, SW480, MCF-7,
A549, and HepG2 [17-19].
Our findings indicate that a new 4-arylidene curcumin
analogue, T83, through inhibition of Jab1, exerts an
antitumor effect in CNE2 and CNE2R cells by reducing
cell growth, arresting the cell cycle, and increasing apop-
tosis. Furthermore, T83 sensitizes NPC to radiotherapy.
This work identifies T83 as a potential targeted therapy
that sensitizes cells prior to conventional radiotherapy,
thus providing more effective treatment for NPC patients.
Methods
Materials
Cell culture reagents and fetal bovine serum (FBS) were
obtained from Invitrogen (Carlsbad, CA, USA). The anti-
bodies used were poly(ADP-ribose polymerase (PARP),
p53 and p27 (BD Biosciences PharMingen, San Diego,
CA, USA), caspase-3 (Cell Signaling Technology, Beverly,
MA, USA), Jab1 (Santa Cruz, CA, USA), and β-actin
(Sigma-Aldrich, St. Louis, MO, USA). Oligofectamine re-
agent was from Invitrogen, the Western Lightning Chemi-
luminescence Plus reagent was from Thermo Scientific
Pierce (Rockford, IL, USA), MTT and DMSO were from
sigma (St. Louis, MO, USA). The Annexin-V/propidium
iodide (PI) kit was from BD Biosciences (Palo Alto, CA,
USA). T83, which was synthesized in our laboratory, was
dissolved in dimethyl sulfoxide (DMSO) to prepare a 10
mM stock solution and stored at −20°C.
Synthesis of T83
The procedure used for the synthesis of T83 was described
previously [19]. Generally, an amount of 1.0 mmol of 1, 3-
diketones curcumin analogs [20] and 2 mmol of the corre-
sponding benzaldehyde as well as 25 mL toluene were
added to a three-neck rounded flask equipped with a
water dispenser. Pyridine (4.0 mg, 0.05 mmol, in 0.1 mL
toluene) and acetic acid (4.8 mg, 0.08 mmol, in 0.1 mLtoluene) were added as catalysts. The reaction mixture
was stirred in 140°C overnight, and the generated water
was removed by water dispenser during the whole reac-
tion. Then the reaction mixture was washed with water
(10 mL, twice) to remove pyridine and acetic acid. Next
the organic layer was evaporated under vacuum to get raw
product. Finally the product was purified by using silica
gel column chromatography.Cell lines and culture conditions
The human NPC cell lines CNE1(well-differentiated)
and CNE2 (poorly differentiated) were obtained from
the Experimental Animal Center of Sun Yat-Sen Univer-
sity. The radioresistant NPC cell line CNE2R was gener-
ated from parental CNE2 cells as previously described
[6] and identified by analysis of DNA microsatellite short
tandem repeats (STR) (see additional file 1). The NPC
cells were cultured in RPMI-1640 medium with 10% FBS
and antibiotics (100 U/mL of penicillin and 100 μg/mL of
streptomycin) in cell culture incubators at 37°C and aired
with 5% CO2. Cells were γ-irradiated with use of a JL
Shepherd and Associates (San Fernando, CA, USA) Mark
I-30 137Cs irradiator at MD Anderson Cancer Center.MTT cell viability assay
The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide (MTT) assay was used to evaluate cell viability,
as described previously [8]. Briefly, NPC cells were
seeded in 96-well plates (2000 cells/well) in RPMI-1640
medium with 10% FBS. The following day, the cells were
treated with indicated concentration of T83 or curcumin
and incubated for 48 h. A total of 20 μL of MTT (5 mg/
mL) was added to each well and incubated for 3.5 h.
The medium was discarded, and 150 μL of DMSO was
added to each well and incubated for 10 min. The ab-
sorbance was read at 570 nm. The concentration of drug
required to obtain 50% maximal inhibition in cell viabil-
ity was indicated by IC50.Colony formation assay
We performed the colony formation assay as previously
described [8]. Generally, the NPC cells (200 cells/well)
were plated in six-well plate for growth analysis in
RPMI-1640 medium with 10% FBS. The following day,
the cells were treated with indicated doses of T83. The
NPC cells were grown at 37°C for 12 days. The effect of
the drugs on growth was determined by colony growth.
Colonies were stained with 0.1% crystal violet and scored
by counting with an inverted microscope, using the
standard definition of a colony consisting of 50 or more
cells. Numbers were normalized as a percentage of col-
onies formed in DMSO treatment.
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cytometry
The treated cells were collected and fixed overnight in
75% cold ethanol at 4°C. Cells were then washed twice
in cold phosphate-buffered saline and labeled with PI
(Sigma-Aldrich), as previously described [8], and analyzed
immediately after staining with use of an Epics Elite
flow cytometer (Coulter Corporation, Miami, FL, USA)
and WinMDI29 software.
Flow cytometric analysis, described previously [8], was
used to differentiate between living, early apoptotic, late
apoptotic/necrotic, and necrotic cells by staining withFigure 1 T83 inhibited viability of NPC cells. Chemical structures of T83
curcumin (B) or T83 (C) for 48 h or exposed to 0.5 μM T83 (D) for 24, 48, a
(E) Clonogenic survival of NPC cells treated with curcumin. (F) Representat
(G) Quantification of colonies. All data represent three independent experimAnnexin V and PI. Briefly, after the indicated treatment,
all of the cells were collected and resuspended in 100 μL
of binding buffer containing Annexin V and PI, according
to the manufacturer’s recommendations. Quantification of
Annexin V and PI binding was performed by a FACScan
flow cytometer (Becton-Dickinson).
Small interfering RNA transfection
The negative control small interfering RNA (siRNA;
siControl 3) and siRNA targeting human Jab1/CSN5
(siCOPS5 #18546) were purchased from Ambion, Inc.
(Austin, TX, USA). Transient transfections of NPC cells(A). NPC cells were incubated with various concentrations of
nd 72 h; cell viability was then quantified by the MTT assay.
ive results of colony formation assays with CNE2 and CNE2R cells.
ents, mean ± s.d. *P < 0.05, **P < 0.01.
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Oligofectamine (Invitrogen) protocol with 5 nmol siRNA in
RPMI-1640 with 10% FBS and no penicillin-streptomycin.
Cell extracts and immunoblotting
Cells in the log phase of growth were collected, washed
twice in cold phosphate-buffered saline, and lysed as
described previously [7]. Proteins in the total cell lysates
were separated by 10% sodium dodecyl sulfate–poly-
acrylamide gel electrophoresis (SDS-PAGE), transferred
to nitrocellulose membranes, and probed with anti-Jab1,
anti-p53, anti-p27, anti-PARP, and anti-caspase-3. actin
was used as the internal positive control for all immuno-
blots. Immunoreactive bands were detected with use ofFigure 2 T83 induced cell cycle arrest and apoptosis in NPC cells. (A)
determined by flow cytometric analysis. Left, NPC cells were treated with D
fixed in ethanol and stained with propidium iodide. Right, Quantification o
indicated concentration of T83 for 48 h and then stained with Annexin-V/P
apoptosis. All data represent three independent experiments, mean ± s.d. *horseradish peroxidase–conjugated secondary antibodies
with the Western Lightning Chemiluminescence Plus re-
agent. Protein levels were quantified with use of ImageJ
software (National Institute of Mental Health, Bethesda,
MD, USA; http://rsb.info.nih.gov/ij). Activities of PARP
and caspase-3 were measured as the proportion of cleav-
age band intensity to the total bands and were calculated
as follows: % PARP or caspase-3 = 100% × Tc/Tt, where
Tc is the intensity value of the cleavage bands and Tt is
the intensity value of total bands.
Statistical analysis
Statistical analysis of the results was performed by using
the Student’s t test for only two groups or by using one-The effects of T83 on cell cycle distribution in NPC cells were
MSO control (0) or indicated concentration of T83 for 24 h and then
f G2/M phase. (B) NPC cells were treated with DMSO control (0) or
I and detected by flow cytometry. Right, Quantification of cell
P < 0.05, **P < 0.01.
Figure 3 T83 inhibited Jab1 in a dose- and time-dependent
manner in NPC cells. Cells from NPC cell lines were treated with
and without T83 at the specified concentrations for 24 h (A) or
exposed to 2 μM T83 for various time points (B). Expression of Jab1,
p53, p27 and β-actin were examined by Western blotting (C). DMSO
was used as control in “0” groups.
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ferences between groups were considered statistically
significant at P < 0.05. All computations were performed
with SPSS 19.0 (SPSS, Chicago, IL, USA).
Results
T83 inhibited cell viability
We first examined the cytotoxicity of T83 by assessing
CNE1, CNE2 and CNE2R cells. We exposed cells from
NPC cell lines to various concentrations of T83. In our
studies, T83 showed growth-suppressive activity in the
NPC cell lines tested in a dose- and time-dependent
manner (Figure 1C and 1D). However, T83 exhibited
greater inhibition than curcumin. IC50 values of T83 were
0.34 μM for CNE1, 0.39 μM for CNE2 and 0.27 μM for
CNE2R, respectively, which are substantially more potent
than curcumin (IC50 values 7.5 μM, 8.1 μM and 6.7 μM)
(Figure 1B).. In addition, we performed a colony formation
assay to determine the effect of T83 on NPC cells’ pro-
liferation. As expected, T83 significantly inhibited col-
ony formation, with more than 99% inhibition at 0.5 μM
treatment in the cell lines tested (Figure 1F and G),
while the survival rated reduced only 10% (CNE2) and
7% (CNE2R) at the same concentration of curcumin
treatment (Figure 1E). These results demonstrated that
T83 was more potent than curcumin in inhibiting cell
viability and proliferation in NPC cells.
T83 induced cell cycle arrest and apoptosis in NPC
Consistent with our observations in NPC cells, flow
cytometric analysis revealed that T83 induced cell cycle
arrest in CNE1 cells at the G2/M phase, with the
percentage of G2/M cells changing from 7.5% in
DMSO-treated controls to 16.1% with 0.4 μM T83 treat-
ment for 24 h. For the CNE2 and CNE2R cells, we got
similar results: the proportion of G2/M phase cells
changed from 13.7% to 33.2% in CNE2 cells and from
11.9% to 52.5% in CNE2R cells (Figure 2A).
We next determined whether T83-induced cell viability
inhibition is followed by increased apoptosis. NPC cells
were treated with T83 for 48 h and analyzed by Annexin-
V and PI staining, which detects apoptosis. Treatment of
NPC cells with T83 resulted in 10 times more apoptotic
CNE1 cells, 2 times more CNE2 cells and 4.8 times more
apoptotic CNE2R cells (Figure 2B).
Inactivation of Jab1 by T83 is dose- and time-dependent
To further determine the effect of T83 on Jab1 inactiva-
tion in NPC, we exposed CNE2 and CNE2R cells to vari-
ous concentrations of T83. As shown in Figure 3A and
3B, T83 inhibited Jab1 activation in a dose- and time-
dependent manner. As Jab1 can promote the degradation
of p27 [7] and p53 [21], we further explored the effect of
T83 on these two proteins. As expected, we found that thedecrease of Jab1 induced by T83 treatment was associated
with an increase of p27 and p53 (Figure 3C). These data
suggest that T83 inhibits Jab1 activity in NPC.
Jab1 expression was associated with T83 efficacy
To further explore the role of Jab1 in T83 action, we
sought to determine whether downregulation of Jab1
would influence T83 efficacy. Thus, NPC cells were
transfected with Jab1 siRNA, and cell survival was mea-
sured by the colony formation assay. Jab1 knockdown of
CNE2 cells resulted in increased T83-induced cell inhib-
ition, with 23% and 17% higher cell survival inhibition
than that seen in control cells transfected with a vector
at 0.05 and 0.1 μM T83, respectively (Figure 4C, left).
Similar results were seen in CNE2R cells transfected
with Jab1 siRNA, which displayed increased T83-
induced cell inhibition, with 61% and 29% higher cell
survival inhibition than that seen in control cells
transfected with a vector at 0.05 and 0.1 μM T83, re-
spectively (Figure 4C, right).
Consistent with the observations described above,
CNE2 cells with reduced Jab1 expression showed in-
creased efficacy of T83 (0.5 and 2 μM) compared with
control cells transfected with scrambled siRNA; the hy-
podiploid (sub-G1) DNA content, reflecting apoptosis,
was increased by 78% and 36%, respectively, at these
concentrations (Figure 4B, left). The CNE2R cells be-
haved similarly: cells in the sub-G1 phase increased by
Figure 4 Jab1 knockdown enhanced the effects of T83 on cell viability inhibition and apoptosis induction. CNE2 cells (left) and CNE2R
cells (right) were transfected with control siRNA (Cont-si) or Jab1 siRNA (Jab1-si) and then exposed to the indicated doses of T83 for 48 h; they
were then examined for colony formation (A), sub-G1 (B), and cleaved caspase-3 (C-Caspase 3) (C). Protein levels were quantified with use of
ImageJ software. All data represent three independent experiments, mean ± s.d. DMSO was used as control in “0” groups.
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concentrations of T83. Similar results were seen when we
tested caspase-3 cleavage. CNE2 cells (Figure 4C, left) and
CNE2R cells (Figure 4C, right) transfected with Jab1
siRNA displayed increased T83-induced caspase-3 cleav-
age compared with control cells. Considering our findings
together, we conclude that Jab1 levels were associated with
T83 efficacy.
T83 sensitizes NPC cells to radiotherapy
Because radiotherapy is the main treatment for NPC, we
investigated whether T83 is involved in the antitumor ef-
fects of radiotherapy. We first used the colony formation
assay to verify the effects of radiotherapy on CNE2 and
CNE2R cells. We observed results similar to those previ-
ously reported [6], that CNE2R cells are more resistantto irradiation (IR) (Figure 4A). We next used a subopti-
mal dose (≤IC10) of T83 to examine whether T83 in-
creased the sensitivity of NPC cells to IR. As expected,
NPC cells treated with T83 showed increased sensitivity
to IR compared with control cells treated with IR alone.
The survival rates of CNE2 cells treated with T83 were
reduced by 20% and 44% when exposed to 4 and 8 Gy of
radiation, respectively (Figure 5B), whereas survival rates
of CNE2R cells treated with T83 were reduced by 47%
and 57%, respectively, at these exposures (Figure 5C).
We further examined whether T83 could enhance IR-
induced apoptosis in NPC cells. We found that IR treat-
ment increased apoptosis in T83-treated cells more than
in control cells, i.e., by 70% in CNE2 cells and by 140%
in CNE2R cells, as measured by PI staining (Figure 5D).
Proteolytic cleavage of PARP and cleaved caspase-3 are
Figure 5 T83 sensitized NPC cells to radiotherapy. NPC cells were treated with IR alone or together with 0.05 μM T83 for 48 h and were then
examined for colony formation (A) (B) (C), PI staining (D), and cleaved PARP (C-PARP) and caspase-3 (C-Caspase-3) (E). DMSO was used as control
in “Cont” groups.
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ined the effects of T83 on the proteolytic cleavage of
PARP and cleaved caspase-3 in response to IR. Com-
pared with results for the control cells, IR consistently
induced more proteolytic cleavage of PARP (35% change
in CNE1, 37% change in CNE2 cells, 24% change in
CNE2R cells) and cleaved caspase-3 (86% change in
CNE1, 41% change in CNE2 cells, 83% change in CNE2R
cells) in T83-treated cells (Figure 5D).
Discussion
In the current study, we have presented evidence showing
the effective inhibition of Jab1 by the new 4-arylidene
curcumin analogue, T83, which resulted in antitumoreffects in NPC cells. These findings suggest that T83 may
be effective in suppressing NPC cell growth in patients
with cancer.
We first confirmed that a synthetic analogue of
curcumin, T83, could significantly inhibit cell prolifera-
tion in NPC cells. T83 is highly effective in inhibiting
cell viability and clone formation in NPC cell lines, and
its IC50 value is much lower than the IC50 values of
other curcumin analogues [17]. Furthermore, we have
shown that T83 can arrest the cell cycle at the G2/M
phase and induce apoptosis in a dose-dependent man-
ner. Previous studies had shown that cells in the G2/M
phase are the most sensitive to radiation and that tumor
cells in this phase are the most responsive to IR and
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radioresistant CNE2R cells in the G2/M phase increased
significantly in a dose-dependent way. All of these data
supported T83’s effect on reversing radioresistance by
increasing G2/M phase accumulation.
Because Jab1 is overexpressed in many cancers includ-
ing NPC [7], suppression of Jab1 contributes to the sen-
sitivity of cisplatin chemotherapy and radiotherapy [8].
Inhibiting the Jab1 signaling pathway may be an effective
strategy in the treatment of NPC, and we here presented
the first evidence of T83 activity in NPC. We also found
that T83 is effective in inhibiting Jab1 expression in a
dose- and time-dependent manner. Given these findings,
we examined the potential effects of Jab1 on T83’s activity
in NPC. Knockdown of Jab1 enhanced T83’s activity
against NPC cells.
Interestingly, all of our experiments showed that
radiation-resistant cells (CNE2R) are more sensitive to
T83 than the parental CNE2 cells; we therefore specu-
lated that T83 possibly sensitizes NPC cells to radiother-
apy. To test this hypothesis, we selected a suboptimal
dose (≤IC10) of T83 to examine whether T83 increased
the sensitivity of NPC cells to IR. Our study suggested
that T83 treatment in combination with radiotherapy
improve the response of NPC to radiotherapy.Conclusions
Taken together, our results indicated that T83 exhibits
enhanced antitumor activity in NPC cells. Our findings,
which demonstrated that T83 inhibited Jab1 and sup-
ported T83 as an anticancer agent, could have important
clinical relevance, namely, that administration of T83
could become part of an effective therapeutic regimen
for NPC.Additional file
Additional file 1: STR profiling of CNE2 and CNE2R.Abbreviations
DMSO: Dimethyl sulfoxide; FBS: Fetal bovine serum; IC50: Concentration of
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